Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer

Cancer Epidemiology

Volumn 37, Issue 6, 2013, Pages 985-992

  Pang, Hui ^a   Lu, Hailing ^a   Song, Hongtao ^a   Meng, Qingwei ^a   Zhao, Yanbin ^a   Liu, Na ^a   Lan, Fei ^a   Liu, Ying ^a   Yan, Suhong ^a   Dong, Xiaoqun ^b   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Catenin; Breast cancer; E cadherin; Osteopontin c; Survival

Indexed keywords

BETA CATENIN; OSTEOPONTIN; OSTEOPONTIN C; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST CANCER; CAMS; CELL ADHESION MOLECULES; DFS; DISEASE-FREE SURVIVAL; E-CADHERIN; ER; ESTROGEN RECEPTOR; HER-2/NEU; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; OPN; OS; OSTEOPONTIN; OSTEOPONTIN-C; OVERALL SURVIVAL; PN; POSITIVE LYMPH NODE; PR; PROGESTERONE RECEPTOR; SURVIVAL; Β-CATENIN;

ADOLESCENT; ADULT; BETA CATENIN; BREAST; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84888301068     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.08.005     Document Type: Article

References (51)

1. Hortobagyi G.N., de la Garza Salazar J., Pritchard K., Amadori D., Haidinger R., Hudis C.A., et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005, 6:391-401.
2. Cowin P., Rowlands T.M., Hatsell S.J. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005, 17:499-508.
3. Wittekind C., Neid M. Cancer invasion and metastasis. Oncology 2005, 69(Suppl. 1):14-16.
4. Oka H., Shiozaki H., Kobayashi K., Inoue M., Tahara H., Kobayashi T., et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993, 53:1696-1701.
5. Lim S.C., Lee M.S. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 2002, 9:915-928.
6. Gonzalez M.A., Pinder S.E., Wencyk P.M., Bell J.A., Elston C.W., Nicholson R.I., et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol 1999, 187:523-529.
7. Kowalski P.J., Rubin M.A., Kleer C.G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003, 5:R217-R222.
8. Chen Y., Shi H.Y., Stock S.R., Stern P.H., Zhang M. Regulation of breast cancer-induced bone lesions by beta-catenin protein signaling. J Biol Chem 2011, 286:42575-42584.
9. Sodek J., Ganss B., McKee M.D. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303.
10. Tuck A.B., O'Malley F.P., Singhal H., Tonkin K.S., Harris J.F., Bautista D., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997, 121:578-584.
11. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
12. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008, 122:889-897.
13. Patani N., Jouhra F., Jiang W., Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28:4105-4110.
14. Uehiro N., Horii R., Iwase T., Tanabe M., Sakai T., Morizono H., et al. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer. Breast Cancer 2013, (Epub ahead of print).
15. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer, I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41:154-161.
16. Leong A.S., Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 2011, 78:99-114.
17. Chakraborty G., Jain S., Behera R., Ahmed M., Sharma P., Kumar V., et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006, 6:819-830.
18. Asgeirsson K.S., Jonasson J.G., Tryggvadottir L., Olafsdóttir K., Sigurgeirsdóttir J.R., Ingvarsson S., et al. Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur J Cancer 2000, 36:1098-1106.
19. Rasbridge S.A., Gillett C.E., Sampson S.A., Walsh F.S., Millis R.R. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol 1993, 169:245-250.
20. Dolled-Filhart M., McCabe A., Giltnane J., Cregger M., Camp R.L., Rimm D.L. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006, 66:5487-5494.
21. Sung V., Gilles C., Murray A., Clarke R., Aaron A.D., Azumi N., et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 1998, 241:273-284.
22. Shevde L.A., Samant R.S., Paik J.C., Metge B.J., Chambers A.F., Casey G., et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006, 23:123-133.
23. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006, 12:3337-3343.
24. Hedley B.D., Welch D.R., Allan A.L., Al-Katib W., Dales D.W., Postenka C.O., et al. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 2008, 123:526-534.
25. Weintraub A.S., Schnapp L.M., Lin X., Taubman M.B. Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Lab Invest 2000, 80:1603-1615.
26. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm 2011, 26:165-173.
27. Teti A., Farina A.R., Villanova I., Tiberio A., Tacconelli A., Sciortino G., et al. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer 1998, 77:82-93.
28. Denhardt D.T., Chambers A.F. Overcoming obstacles to metastasis - defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994, 56:48-51.
29. Feng B., Rollo E.E., Denhardt D.T. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis 1995, 13:453-462.
30. Liaw L., Almeida M., Hart C.E., Schwartz S.M., Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994, 74:214-224.
31. Tuck A.B., Elliott B.E., Hota C., Tremblay E., Chambers A.F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 2000, 78:465-475.
32. Wang X., Chao L., Ma G., Chen L., Tian B., Zang Y., et al. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 2008, 38:438-446.
33. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
34. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
35. Ribeiro-Silva A., Oliveira da Costa J.P. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 2008, 23:154-160.
36. Cobanoglu U., Ersoz S., Turgutalp H., Reis A., Ozoran Y. Correlation of E-cadherin expression with clinicopathological parameters in breast carcinoma. Saudi Med J 2004, 25:1024-1027.
37. Mi Z., Guo H., Kuo P.C. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes 2009, 2:119.
38. Bankfalvi A., Terpe H.J., Breukelmann D., Bier B., Rempe D., Pschadka G., et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999, 34:25-34.
39. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
40. Michaelson J.S., Silverstein M., Sgroi D., Cheongsiatmoy J.A., Taghian A., Powell S., et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003, 98:2133-2143.
41. Michaelson J.S., Silverstein M., Wyatt J., Weber G., Moore R., Halpern E., et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002, 95:713-723.
42. Sharp J.A., Sung V., Slavin J., Thompson E.W., Henderson M.A. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999, 79:869-877.
43. Duraker N., Caynak Z.C. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes. Cancer 2005, 104:700-707.
44. Lin C., Chien S.Y., Chen L.S., Kuo S.J., Chang T.W., Chen D.R. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009, 9:192.
45. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.
46. Weber G.F., Lett G.S., Haubein N.C. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869.
47. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3:605-611.
48. Weber G.F., Lett G.S., Haubein N.C. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 2011, 25:433-441.
49. Ravindranath A., Yuen H.F., Chan K.K., Grills C., Fennell D.A., Lappin T.R., et al. Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer 2011, 105:542-551.
50. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010, 10:71-81.
51. Gillett C.E., Miles D.W., Ryder K., Skilton D., Liebman R.D., Springall R.J., et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001, 193:433-441.